Dev

The HELIAD is a population-based, multidisciplinary, collaborative study designed to estimate the prevalence and incidence of AD, other dementias, mild cognitive impairment, and other neuropsychiatric conditions of aging in the Greek population and to investigate associations between nutrition and cognitive…

Helsinki Birth Cohort Study (HBCS) 1934-44 is a unique birth study including 13,345 subjects in the epidemiological cohort. The cohort is a longitudinal study cohort with data throughout the life span including prenatal life, early childhood and later life. Besides…

GENFI is a five year longitudinal biomarker cohort study of genetic Frontotemporal Dementia and its associated disorders (including MND/ALS) investigating members of families with a known mutation in GRN or MAPT or an expansion in C9orf72 (including those affected with…

The Dunedin Multidisciplinary Health and Development Study (DMHDS) is an ongoing, longitudinal study of the health, development and well-being of a general sample of New Zealanders. They were studied at birth (1972-73), followed up and assessed at the age of…

The DEAS is a nationwide representative survey of the German population aged 40 and older that combines cross-sectional and longitudinal samples. Participants from baseline samples (drawn every six years) are followed up and enter the different panel samples. Panel data…

The overall goal was to establish a genetic-epidemiological database to shed light on the aging process among the extremely old, focusing on physical and cognitive functioning. In the first wave 2,262 Danes born in 1905 participated in a home-based 2-hour…

CFAS Wales aims to interview a representative sample of 3,750 people aged 65 and over in two areas in Wales (Gwynedd and Swansea). Using established and standardised techniques it will collect data that will enable the investigation of cognitive impairment,…

The AMPLE study has been set up to investigate differences and outcomes in those with Lewy body dementia with and without concurrent Alzheimer’s disease The principle aim of AMPLE is to undertake amyloid PET imaging in Lewy Body Dementia (LBD)…

Aims & objective To find out the known as well as some new factors which increase the risk of occurrence of stroke (half body paralysis, Lakwa) and of memory problem and other brain related problems. To identify a group of…

ADNI began in October 2004. The overall goal is to validate biomarkers for Alzheimer’s disease clinical trials. One aim is to find, validate and standardize more sensitive and accurate methods to detect Alzheimer’s disease at earlier stages and mark its…